Patients with CTNNB1 exon 3 mutation had a mean DFS of 73.79 ± 41.59 (range, 10–144) months compared with 81.00 ± 44.32 (range, 0–174) months for patients with wild-type CTNNB1 exon 3 tumours (p = 0.010) (Fig. 1A). This evidence concerns the gene CTNNB1 and neoplasm.